Folate Supplementation in Schizophrenia

Completed · Phase 4 · Has a placebo group

Conditions studied: Schizophrenia

In brief

This study aims to examine factors potentially contributing to differences in blood folate, homocysteine or B12 levels between schizophrenia patients, to test the hypothesis that low folate is associated with negative symptoms, and to examine the efficacy of folate supplementation for reducing negative symptoms.

Key facts

Study ID

NCT00249288

Run by

Massachusetts General Hospital

People needed

46

Starts

2003-12-01

Expected to finish

2008-06-01

Last updated by the study team

2018-04-05

Who can join

Age: 18 and older, up to 68. Sex: any. Healthy volunteers: not accepted.

You may qualify if…

• Schizophrenia, any subtype
• Ages 18-68
• Male or female
• A score at least a 3 (moderate or greater severity) on at least one of the SANS global assessment subscales, with the exception of the attention global assessment subscale
• Stable antipsychotic dose for > 6 weeks
• Capable of providing informed consent

You may not qualify if…

• Unstable medical illness
• Substance abuse
• Megaloblastic anemia
• Non-english speaking

Where it is running

• Massachusetts General Hospital — Boston, Massachusetts, United States

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.